3
Shared Docs
3
Same-Page
9 / 3
Mentions
From: Boris Nikolic To: "Jeffrey Epstein ([email protected])" <[email protected]> Subject: FW: Materials at request of David Rubenstein Date: Fri, 29 Apr 2011
h you as you are developing it. EFTA00707964 Please keep me posted. If you have any plans of visiting Seattle, please let me know All the best Boris From: Ryan Schwarz [mailto Sent: Wednesday, March 09, 2011 11:28 AM To: Boris Nikolic Subject: Materials at request of David Rubenstein Boris,
From: Boris Nikolic To: "Jeffrey Epstein ([email protected])" <je
n the eventual fund placement memo and presentation. The other is a confidential summary of an investment opportunity that we are pursuing involving Xigris, the sole approved, on-market drug for severe sepsis. I look forward to seeing you in the morning. Ryan Ryan M. Schwarz Managing Director THE C
From: Boris Nikolic To: "Jeffrey Epstein (I < Subject: FW: Materials at request of David Rubenstein Date: Tue, 04 Feb 2014 07:51:42 +0000 Attachments: NaviMed_Global
ore details with you as you are developing it. Please keep me posted. If you have any plans of visiting Seattle, please let me know All the best Boris From: Ryan Schwarz [mailto: Sent: Wednesday, March 09, 2011 11:28 AM To: Boris Nikolic Subject: Materials at request of David Rubenstein Boris,
From: Boris Nikolic To: "Jeffrey Epstein (I < Subject: FW: Material
n the eventual fund placement memo and presentation. The other is a confidential summary of an investment opportunity that we are pursuing involving Xigris, the sole approved, on-market drug for severe sepsis. I look forward to seeing you in the morning. Ryan Ryan M. Schwarz Managing Director THE C
From: Boris Nikolic To: "Jeffrey Epstein I III ) " Subject: FW: Materials at request of David Rubenstein Date: Fri, 11 Mar 2011 03:17:41 +0000 Attachments: NaviMed_Gl
From: Boris Nikolic To: "Jeffrey Epstein I III ) " Subject: FW: Mate
From: Boris Nikolic To: "Jeffrey Epstein I III ) " Subject:
n the eventual fund placement memo and presentation. The other is a confidential summary of an investment opportunity that we are pursuing involving Xigris, the sole approved, on-market drug for severe sepsis. I look forward to seeing you in the morning. Ryan Ryan M. Schwarz Managing Director THE C
Entities connected to both Boris Nikolic and Xigris